Paclitaxel albumin injection, also known as Abraxane, differs from regular paclitaxel in its formulation and method of delivery. The primary distinction lies in the way paclitaxel is bound to the albumin protein in Abraxane, as opposed to being bound to polyoxyethylated castor oil (Cremophor EL) and dehydrated alcohol in regular paclitaxel [1].

The albumin-bound formulation in paclitaxel albumin injection allows for improved solubility and tumor delivery compared to regular paclitaxel [2]. This results in an enhanced therapeutic effect, as well as a reduced risk of hypersensitivity reactions, which are commonly associated with the Cremophor EL-based formulation in regular paclitaxel [3].

Additionally, paclitaxel albumin injection has a different dosing regimen compared to regular paclitaxel. Abraxane is typically administered at a higher dose and frequency, allowing for more convenient and efficient treatment schedules [4].

In summary, paclitaxel albumin injection differs from regular paclitaxel in its formulation, method of delivery, and dosing regimen. These differences contribute to an improved safety profile and enhanced therapeutic effect for paclitaxel albumin injection.

Sources:
[1] <https://www.ncbi.nlm.nih.gov/books/NBK65799/>
[2] <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976949/>
[3] <https://www.drugpatentwatch.com/drugs/abraxane>
[4] <https://www.ncbi.nlm.nih.gov/books/NBK65799/>